Alzheimer’s & Dementia

Filter Your Results

 

News

 

Having Children May Be Associated With Reduced Risk of Dementia and Other Sex-Specific Differences in Dementia

Tuesday, July 24, 2018—While it has long been known that AD is more prevalent in women than men (3:2) in the US, the reasons for this are not fully understood; theories include women's longer li…

Alzheimer’s Association Releases First Clinical Evaluation Guideline

Monday, July 23, 2018—New evidence-based consensus guidelines for the evaluation of cognitive-behavioral symptoms of Alzheimer's disease (AD) and other dementias have been released and strongly…

Meningeal Enhancement Seen on Workup for Memory Loss

Nima Khosravani, MS; Anamaria Shanley, MSN, ARNP-BC; and Ira J. Goodman, MD

July/August 2018—Inflammation in the context of memory loss reminds us of the importance of checking opening pressure on lumbar puncture.

Investigational Tau Modifier Receives Orphan Drug Status for Progressive Supranuclear Palsy

Wednesday, July 18, 2018—The Food and Drug Administration (FDA) has granted an orphan drug designation to ASN120290 (Asceneuron SA, Lausanne, Switzerland) for the treatment of progressive supranuclear…

Phase 2 Confirmatory Trial of Bryostatin-1 for Alzheimer’s Disease Enrolls First Patient

Monday, July 16, 2018—The first individual has been enrolled into a confirmatory phase 2 clinical trial of bryostatin-1 (Neurotrope, New York, NY) for the treatment of persons with Alzheimer’…

IncobotulinumtoxinA Approved for Treatment of Excessive Drooling

Friday, July 13, 2018—The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxin A (Xeomin; Merz, Raleigh, NC) for the treatmen…

Can Patients Unique Brain Imaging Fingerprints Direct Clinical Management?

Tuesday, July 10, 2018—Researchers for the Alzheimer's Disease Neuroimaging Initiative from the Montreal Neurology Institute and Hospital (Montreal, Canada) have published results in the journal…

Positive Results for Potential Alzheimer’s Disease Treatment in Phase 2 Trial

Thursday, July 05, 2018—In one of the first late-stage studies to demonstrate potential disease modifying effects for the treatment of persons with Alzheimer’s disease, a monoclonal antibody to…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.

 
  • BRYN MAWR COMMUNICATIONS III, LLC